Q: What is Vonjo used for?

Vonjo is used to treat myelofibrosis .

Q: How does Vonjo work?

Targeting Specific Enzymes Vonjo is a type of medication known as a kinase inhibitor. It works by blocking the activity of certain proteins in the body, specifically Janus kinase 2 (JAK2) and interleukin-1 receptor-associated kinase 1 (IRAK1). In people with myelofibrosis, these proteins are often overactive. This overactivity sends constant signals to the bone marrow to produce too many blood cells. Over time, this process leads to inflammation and the development of scar tissue (fibrosis) within the bone marrow. This scarring makes it difficult for the marrow to produce healthy blood cells normally. How It Affects the Body By interfering with these signaling pathways, Vonjo helps to regulate the production of blood cells and reduce inflammation. This can lead to several effects: Reduction in spleen size: Myelofibrosis often causes the spleen to enlarge as it tries to take over blood cell production from the scarred bone marrow. Control of symptoms: Blocking these pathways helps reduce the inflammatory signals that contribute to many symptoms of the condition. Vonjo is designed to target these pathways while remaining compatible with low platelet levels, which are the blood cells responsible for clotting.

Q: What are the active ingredients in Vonjo?

The active ingredient in Vonjo is pacritinib .

Q: What are the side effects of Vonjo?

Common side effects of Vonjo may include: diarrhea nausea fatigue and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Vonjo?

Vonjo belongs to the JAK inhibitor and BCL-2 family inhibitor combination drug class.

Q: What is the dosage of Vonjo and how do I take it?

How to Take Vonjo Vonjo is a capsule taken by mouth. It is generally prescribed to be taken twice every day. You may take this medication with or without food. To help you remember your doses, try to take them at the same times each day. Administration Guidelines Swallow the capsules whole. Do not open, break, or chew the capsules. Missed Dose If you forget to take a dose of Vonjo, take it as soon as you realize it. If it is almost time for your next dose, skip the one you missed and continue with your regular schedule. You should not take two doses at once to compensate for a missed dose.

Q: Is Vonjo safe during pregnancy and breastfeeding?

Pregnancy There are no adequate studies on the use of Vonjo in pregnant women to determine drug-associated risks. However, based on findings from animal studies, this medication may cause harm to a developing fetus. It is important to discuss the potential risks and benefits with a healthcare provider if you are pregnant or planning to become pregnant. For individuals of reproductive potential, healthcare providers typically recommend the following: A pregnancy test should be performed before starting treatment to confirm you are not pregnant. Effective birth control (contraception) should be used during treatment and for at least 2 weeks after the final dose. Breastfeeding It is not known if Vonjo passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions in a breastfed child, it is advised that individuals do not breastfeed while taking this medication and for at least 2 weeks after the last dose. Fertility Based on animal studies, Vonjo may impair fertility in both females and males. If you have concerns about future fertility, talk to your healthcare provider before starting treatment.

Q: What is the FDA approval status of Vonjo?

FDA Approval History The U.S. Food and Drug Administration (FDA) granted accelerated approval to Vonjo on February 28, 2022. The approval was based on clinical trial data showing the drug's ability to reduce spleen volume in patients with specific forms of bone marrow disorders. Approved Indications Vonjo is approved for use in adults with intermediate or high-risk primary or secondary myelofibrosis (including post-polycythemia vera or post-essential thrombocythemia myelofibrosis) who have a platelet count below 50 × 10 9 /L. Regulatory Status and Requirements As part of the accelerated approval process, the FDA requires further clinical trials to confirm the drug's clinical benefit. The continued approval of Vonjo for this specific use may depend on the results of these ongoing studies. Currently, Vonjo does not have a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program. However, the FDA-approved labeling includes warnings regarding serious risks, such as severe bleeding ( hemorrhage ), heart rhythm abnormalities ( prolonged QT interval ), and major adverse cardiovascular events.

Question 1

What is Vonjo?

Accepted Answer

Vonjo is a kinase inhibitor that contains the active ingredient pacritinib. It functions by blocking the action of specific enzymes in the body, such as Janus kinase 2, which are involved in cell growth and immune responses.

This medication targets signaling pathways to help manage certain conditions affecting the bone marrow. By inhibiting these proteins, it helps control the abnormal production of blood cells associated with these disorders.

Question 2

What is Vonjo used for?

Accepted Answer

Vonjo is used to treat myelofibrosis.

Question 3

How does Vonjo work?

Accepted Answer

Targeting Specific Enzymes

Vonjo is a type of medication known as a kinase inhibitor. It works by blocking the activity of certain proteins in the body, specifically Janus kinase 2 (JAK2) and interleukin-1 receptor-associated kinase 1 (IRAK1).

In people with myelofibrosis, these proteins are often overactive. This overactivity sends constant signals to the bone marrow to produce too many blood cells. Over time, this process leads to inflammation and the development of scar tissue (fibrosis) within the bone marrow. This scarring makes it difficult for the marrow to produce healthy blood cells normally.

How It Affects the Body

By interfering with these signaling pathways, Vonjo helps to regulate the production of blood cells and reduce inflammation. This can lead to several effects:

Reduction in spleen size: Myelofibrosis often causes the spleen to enlarge as it tries to take over blood cell production from the scarred bone marrow.
Control of symptoms: Blocking these pathways helps reduce the inflammatory signals that contribute to many symptoms of the condition.

Vonjo is designed to target these pathways while remaining compatible with low platelet levels, which are the blood cells responsible for clotting.

Question 4

What are the active ingredients in Vonjo?

Accepted Answer

The active ingredient in Vonjo is pacritinib.

Question 5

What are the side effects of Vonjo?

Accepted Answer

Common side effects of Vonjo may include:

diarrhea
nausea
fatigue
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Vonjo?

Accepted Answer

Vonjo belongs to the JAK inhibitor and BCL-2 family inhibitor combination drug class.

Question 7

What is the dosage of Vonjo and how do I take it?

Accepted Answer

How to Take Vonjo

Vonjo is a capsule taken by mouth. It is generally prescribed to be taken twice every day. You may take this medication with or without food. To help you remember your doses, try to take them at the same times each day.

Administration Guidelines

Swallow the capsules whole.
Do not open, break, or chew the capsules.

Missed Dose

If you forget to take a dose of Vonjo, take it as soon as you realize it. If it is almost time for your next dose, skip the one you missed and continue with your regular schedule. You should not take two doses at once to compensate for a missed dose.

Question 8

Is Vonjo safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate studies on the use of Vonjo in pregnant women to determine drug-associated risks. However, based on findings from animal studies, this medication may cause harm to a developing fetus. It is important to discuss the potential risks and benefits with a healthcare provider if you are pregnant or planning to become pregnant.

For individuals of reproductive potential, healthcare providers typically recommend the following:

A pregnancy test should be performed before starting treatment to confirm you are not pregnant.
Effective birth control (contraception) should be used during treatment and for at least 2 weeks after the final dose.

Breastfeeding

It is not known if Vonjo passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions in a breastfed child, it is advised that individuals do not breastfeed while taking this medication and for at least 2 weeks after the last dose.

Fertility

Based on animal studies, Vonjo may impair fertility in both females and males. If you have concerns about future fertility, talk to your healthcare provider before starting treatment.

Question 9

What forms and strengths does Vonjo come in?

Accepted Answer

Vonjo is available as a capsule for oral administration. The capsules are designed to be swallowed whole and should not be opened, crushed, or chewed.

Question 10

What is the FDA approval status of Vonjo?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Vonjo on February 28, 2022. The approval was based on clinical trial data showing the drug's ability to reduce spleen volume in patients with specific forms of bone marrow disorders.

Approved Indications

Vonjo is approved for use in adults with intermediate or high-risk primary or secondary myelofibrosis (including post-polycythemia vera or post-essential thrombocythemia myelofibrosis) who have a platelet count below 50 × 10 9 /L.

Regulatory Status and Requirements

As part of the accelerated approval process, the FDA requires further clinical trials to confirm the drug's clinical benefit. The continued approval of Vonjo for this specific use may depend on the results of these ongoing studies.

Currently, Vonjo does not have a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program. However, the FDA-approved labeling includes warnings regarding serious risks, such as severe bleeding (hemorrhage), heart rhythm abnormalities (prolonged QT interval), and major adverse cardiovascular events.

Question 11

What should I know about Vonjo and cost?

Accepted Answer

Insurance and Pharmacy Factors

The price of Vonjo is influenced by several factors, including your specific health insurance plan. Your out-of-pocket costs will depend on your plan's deductible, copayment, or coinsurance requirements. Because Vonjo is a specialty medication, it is typically available only through specialty pharmacies rather than standard retail pharmacies.

Financial Assistance

There are several resources available that may help reduce the cost of treatment for eligible patients:

Manufacturer Assistance: Programs may be available to help patients with commercial insurance lower their out-of-pocket expenses through copay cards or similar support.
Patient Assistance Programs: These programs are often designed for individuals who are uninsured or underinsured to help them access necessary medications.
Foundation Support: Some independent charitable organizations provide financial grants to help cover the costs of medications for myelofibrosis and other rare conditions.

Patients are encouraged to contact their insurance provider or a specialty pharmacy to determine their specific coverage and to learn about available support programs.

Vonjo

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Vonjo

Hospitals.net Disclosure